Less specific targeting strategies of the p38-MAPK signaling cascade have shown significant therapeutic potential in the treatment of endocrine resistant breast cancer through inhibition of downstream targets Hsp27 and MAPK (Antoon et al., 2012). Here, HSPB1 is linked to breast carcinoma.